Breakdown | ||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
66.80M | 64.47M | 55.00M | 49.04M | 47.52M | Gross Profit |
32.05M | 29.77M | 34.54M | 24.77M | 28.23M | EBIT |
-2.56M | -2.61M | -218.00K | -10.46M | -10.54M | EBITDA |
-3.76M | -6.20M | 652.00K | -9.46M | -9.63M | Net Income Common Stockholders |
-8.87M | -8.44M | -2.36M | -12.05M | -10.85M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.12M | 3.23M | 5.56M | 3.31M | 3.16M | Total Assets |
31.81M | 35.73M | 37.43M | 34.02M | 38.78M | Total Debt |
15.03M | 15.95M | 18.20M | 23.63M | 17.09M | Net Debt |
13.91M | 12.72M | 12.64M | 20.32M | 13.94M | Total Liabilities |
69.70M | 68.28M | 66.49M | 60.44M | 54.96M | Stockholders Equity |
-37.88M | -32.55M | -29.05M | -26.42M | -16.18M |
Cash Flow | Free Cash Flow | |||
1.92M | 4.99M | 6.02M | -1.71M | -5.74M | Operating Cash Flow |
2.43M | 5.19M | 6.18M | -744.00K | -4.99M | Investing Cash Flow |
-165.00K | -202.00K | -163.00K | -969.00K | -1.12M | Financing Cash Flow |
-1.70M | -4.95M | -3.66M | 2.04M | 2.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $138.54B | 75.09 | 9.03% | ― | 17.60% | 16.84% | |
78 Outperform | $134.90B | 45.53 | 15.26% | 0.93% | 10.23% | -5.74% | |
77 Outperform | $176.84B | 76.96 | 15.62% | ― | 17.24% | 27.76% | |
77 Outperform | $108.02B | 25.60 | 8.42% | 3.32% | 2.72% | 4.48% | |
73 Outperform | $20.30B | 23.00 | 7.24% | 0.94% | 3.84% | -9.29% | |
54 Neutral | $3.93B | -17.35 | -15.99% | 6.44% | 25.52% | -80.16% | |
38 Underperform | $7.15M | ― | 9.26% | ― | ― | ― |
On February 25, 2025, Dr. Patrick Bruno resigned from the Board of Directors of DIH Holding US, Inc., as well as from his roles at its subsidiaries, including Hocoma Medical GmbH and Hocoma AG. The company will not immediately fill his position, reducing the board size to five members. Dr. Bruno’s resignation followed violations of company policies, and a Termination Agreement was established, which includes mutual releases, confidentiality, and non-disparagement clauses. He will receive his salary up to the resignation date but will not receive any bonuses or severance payment.